Evidence‑Based Asthma Management Recommendations (2020 NAEPP)

Pharmacologic Therapy by Asthma Severity

• All adults and adolescents with asthma should receive an inhaled corticosteroid‑containing regimen and should never be managed with a short‑acting β‑agonist (SABA) alone. 1
• Step 1 (intermittent asthma): Use as‑needed SABA for rescue only. 1
• Step 2 (mild persistent asthma – preferred regimen): Daily low‑dose inhaled corticosteroid (ICS) plus as‑needed SABA. 1
• Step 3 (moderate persistent asthma – preferred regimen): Daily low‑dose ICS‑formoterol used both as maintenance and as‑needed reliever (single‑maintenance‑and‑reliever therapy, MART). 1
• Step 3 (moderate persistent asthma – alternative regimen): Daily medium‑dose ICS with as‑needed SABA. 1
• Step 4 (moderate‑severe persistent asthma – preferred regimen): Daily medium‑dose ICS‑formoterol used both as maintenance and as‑needed reliever. 1
• Step 4 (moderate‑severe persistent asthma – alternative regimen): Daily medium‑dose ICS‑LABA with as‑needed SABA, or add a long‑acting muscarinic antagonist (LAMA). 1
• Step 5 (severe persistent asthma – preferred regimen): Daily medium‑high dose ICS‑LABA. 1
• Step 5 (severe persistent asthma – biologic therapy): Consider add‑on biologics (anti‑IgE, anti‑IL‑5, anti‑IL‑5R, anti‑IL‑4/IL‑13) when control remains inadequate. 1
• Step 6 (most severe persistent asthma – preferred regimen): Daily high‑dose ICS‑LABA or oral systemic corticosteroids; biologics should be strongly considered. 1

Assessment Before Escalating Therapy

• Environmental trigger assessment: Identify and address allergen exposures, irritants, and tobacco smoke as part of routine evaluation before stepping up treatment. 2
• ICS dose optimization: Increase inhaled corticosteroid dose up to the equivalent of 2000 µg beclomethasone daily before adding additional controller agents. (High‑quality evidence) 3

Self‑Management and Patient Education

• Written asthma action plan: Every patient should receive a personalized, written plan that includes daily management instructions, recognition of worsening asthma, specific actions for exacerbations, and clear criteria for seeking urgent care. (Supported by multiple sources) [3][2]
• Key components of the action plan:
  
  • Monitoring of symptoms, peak flow, and medication use. 2
  • Pre‑arranged actions the patient can take independently. 3
  • Color‑coded zones (green/yellow/red) with written guidance. 4
• Self‑management actions:
  
  • Initiate or increase inhaled steroids when symptoms worsen. 5
  • Self‑administer oral corticosteroids when peak flow falls below ~60 % of personal best. 4
  • Seek urgent medical attention if prescribed actions are ineffective. 4
• Education topics:
  
  • Distinguish “relievers” (bronchodilators) from “preventers” (anti‑inflammatory agents). 5
  • Recognize nocturnal symptoms as a warning sign of poor control. 5

Acute Exacerbation Management

• Escalation of nebulized β‑agonist: If no improvement after initial therapy, increase nebulized SABA frequency to every 15 minutes. (Moderate‑quality evidence) 6
• Adjunctive IV therapy: Consider IV aminophylline (250 mg over 20 min) or parenteral β‑agonist for severe attacks, avoiding aminophylline bolus in patients already on oral theophylline. (Moderate‑quality evidence) 6
• Criteria for ICU admission (life‑threatening asthma):
  
  • Deteriorating peak flow, hypoxia (PaO₂ < 8 kPa despite 60 % O₂), or hypercapnia (PaCO₂ > 6 kPa). 6
  • Clinical signs such as exhaustion, feeble respiration, altered mental status, or impending respiratory arrest. 6
• Contraindicated treatments:
  
  • Antibiotics unless a bacterial infection is documented. 6
  • Any sedative agents. 6
  • Percussive physiotherapy (no proven benefit). 6

Hospital Discharge and Follow‑Up

• Discharge criteria (all must be met):
  
  • Peak flow > 75 % of predicted or best value. 6
  • Diurnal variability < 25 %. 6
  • Absence of nocturnal symptoms. 6
• Mandatory discharge medications:
  
  • Inhaled corticosteroid at a higher dose than pre‑admission level. 5
  • Peak flow meter together with a written self‑management action plan. 2
• Follow‑up schedule:
  
  • General practitioner review within 1 week of discharge. 6
  • Respiratory specialist review within 1 month of discharge. 6

Specialist Referral Indications

• Referral to a respiratory physician is advised when a patient requires Step 4 or higher therapy (or earlier if control remains inadequate). 1
• Additional referral triggers (supported by evidence):
  
  • Diagnostic uncertainty (e.g., elderly smokers with wheeze). 5
  • Possible occupational asthma. 2
  • Catastrophic or “brittle” asthma presentations. 5
  • Persistent symptoms despite high‑dose inhaled steroids. 5
  • Need for long‑term nebulized bronchodilator therapy. 3
  • Pregnancy with worsening asthma. 3
  • Asthma that significantly impairs lifestyle despite optimized therapy. 4
  • Recent hospital discharge for asthma. 4

Adjunctive Therapies

• Fractional exhaled nitric oxide (FeNO): Conditionally recommended as part of an ongoing monitoring strategy to aid diagnosis and treatment adjustment. (Conditional recommendation) 1
• Allergen mitigation: Recommended only for patients with documented exposure and confirmed sensitivity; strategies must be allergen‑specific and multimodal. (Conditional recommendation) 1
• Immunotherapy: Subcutaneous immunotherapy is recommended as an adjunct to standard pharmacotherapy for patients with symptomatic, allergen‑sensitized asthma. (Conditional recommendation) 1

Evidence‑Based Pharmacologic Management of Asthma (Cited Guidelines)

Stepwise Controller Therapy

• For patients whose asthma remains uncontrolled on standard doses, increase inhaled corticosteroid (ICS) therapy up to a daily equivalent of 2000 µg beclomethasone before adding any additional controller agents. 7

• At every clinic visit, verify correct inhaler technique and, when metered‑dose inhaler (MDI) technique is suboptimal, provide a large‑volume spacer device. 7

• Prior to escalating therapy, assess medication adherence to ensure poor control is not due to non‑compliance. 7

• After a period of 1–3 months of clinical stability, a stepwise reduction of treatment intensity may be considered. 7

Acute Exacerbation Management

Immediate Pharmacologic Treatment

• Administer high‑dose nebulized short‑acting β₂‑agonists (e.g., salbutamol 5 mg or terbutaline 10 mg) together with supplemental oxygen. [8][9]

• Give systemic corticosteroids promptly: prednisolone 30–60 mg orally or hydrocortisone 200 mg intravenously. [8][10]

• For life‑threatening presentations, add nebulized ipratropium bromide 0.5 mg to the β₂‑agonist regimen. [8][10]

• Consider intravenous aminophylline (250 mg over 20 min) or parenteral β₂‑agonist for severe attacks, but avoid a bolus aminophylline in patients already receiving oral theophylline. [8][10]

Monitoring and Escalation

• Measure peak expiratory flow (PEF) 15–30 minutes after treatment initiation. [8][11]

• If no improvement in PEF is observed within 15–30 minutes, increase nebulized β₂‑agonist frequency to every 15 minutes. [8][11]

• Continue high‑dose systemic steroids (prednisolone 30–60 mg daily or IV hydrocortisone 200 mg every 6 hours) throughout the acute episode. [8][11]

Hospital Discharge Criteria & Prescriptions

• Discharge is permitted only when the patient’s PEF exceeds 75 % of predicted (or best) value, diurnal variability is < 25 %, and nocturnal symptoms have resolved. [8][11]

• All discharged patients should receive:

  • Prednisolone 30 mg daily (or higher) for 1–3 weeks to complete the steroid course. [8][11]
  • Inhaled corticosteroid at a higher dose than pre‑admission to maintain control. [8][11]
  • Inhaled or nebulized short‑acting β₂‑agonist as needed for symptom relief. [8][11]
  • A peak flow meter together with a written self‑management action plan. [11][12]

Adjunctive and Contraindicated Measures

• Antibiotics should be prescribed only when a bacterial infection is documented. [8][11]

• Sedation is absolutely contraindicated in acute asthma attacks. [8][11]

• Percussive physiotherapy provides no benefit and is not recommended. [8][11]

Post‑Discharge Follow‑Up

• Patients must see their general practitioner within 1 week of hospital discharge. [11][12]

• A respiratory physician review should be arranged within 1 month of discharge. [11][12]

Antibiotic Management of Chest Infections in Asthma Patients

When Antibiotics Are Indicated

• Antibiotics should be prescribed only when radiographic evidence of pneumonia (e.g., lobar consolidation on chest X‑ray) is present. 13
• Antibiotics are indicated when the patient has fever together with a documented bacterial infection. 14
• Clinical signs of bacterial pneumonia (e.g., productive cough with pleuritic chest pain, tachypnea, elevated inflammatory markers) warrant antibiotic therapy, whereas simple bronchitis does not. 15

When Antibiotics Are Not Indicated

• Viral respiratory infections (most commonly rhinovirus) are the predominant trigger of asthma exacerbations and do not benefit from antibiotics. 16
• Purulent‑appearing sputum alone is an unreliable marker of bacterial infection because eosinophilic inflammation in asthma can also discolor sputum. 16
• Routine antibiotic use in asthma exacerbations without documented bacterial infection provides no clinical advantage; two small trials (total ≈ 121 patients) showed no benefit. 16
• Antibiotics are contraindicated for asthma exacerbations lacking documented bacterial infection. 13

First‑Line Outpatient Therapy for Community‑Acquired Pneumonia (CAP)

• Amoxicillin 500–1000 mg every 8 h is the preferred regimen for patients without cardiopulmonary disease or risk factors for drug‑resistant Streptococcus pneumoniae (DRSP). 15
• Amoxicillin‑clavulanate 1 g every 8 h is an alternative when regional prevalence of β‑lactamase‑producing Haemophilus influenzae is high. 15

Patients With Risk Factors for DRSP (e.g., recent antibiotics, age > 65, immunocompromise, diabetes, chronic cardiac/hepatic/renal disease)

• High‑dose amoxicillin‑clavulanate (2 g twice daily or 4 g/250 mg daily) provides coverage for penicillin‑nonsusceptible pneumococcus. 17

Penicillin‑Allergic Patients

• Doxycycline 100 mg every 12 h is recommended as first‑line therapy. 15
• For severe infection, a respiratory fluoroquinolone (levofloxacin or moxifloxacin) may be used. 18
• Macrolides (azithromycin, clarithromycin) should be avoided as first‑line agents because resistance in S. pneumoniae exceeds 40% in many regions. 17

Hospitalized Patients

Medical Ward (non‑ICU)

• Second‑ or third‑generation cephalosporin (e.g., cefuroxime 750–1500 mg IV every 8 h or ceftriaxone 1 g IV daily) plus a macrolide (erythromycin 1 g IV every 8 h or azithromycin) is recommended. 15
• Alternative: monotherapy with an antipneumococcal fluoroquinolone (levofloxacin or moxifloxacin). 18

ICU Admission

• β‑lactam active against DRSP (ceftriaxone or cefotaxime) plus either azithromycin or a fluoroquinolone. 18
• If aspiration or lung abscess is suspected, add amoxicillin‑clavulanate 2 g IV every 6 h or clindamycin 600 mg IV every 8 h. 15

Duration of Therapy

• Minimum 7–10 days of treatment for uncomplicated community‑acquired pneumonia. 15
• Five‑day courses may be sufficient for uncomplicated cases with a good clinical response. 17

Critical Pitfalls to Avoid

• Do not prescribe antibiotics for asthma exacerbations without documented bacterial infection (explicit contraindication). 13
• Avoid trimethoprim‑sulfamethoxazole because resistance rates are high (≈ 50 % in S. pneumoniae, ≈ 27 % in H. influenzae). 17
• Fluoroquinolones should not be first‑line unless there is a penicillin allergy or treatment failure, due to adverse‑effect profile and rising resistance. 19
• Macrolides should not be used alone for empiric pneumonia treatment because of widespread resistance. 17